Mister Spex SE : A still difficult start to the year, marked improvement anticipated for the rest of the year

>Modest growth in Q1 at +6%, a visible loss on adjusted EBITDA but FY guidance maintained - Q1 2022 sales were € 47.2m, up 6% y-o-y with adjusted EBITDA at -€ 4.6m (vs +€ 0.7m in Q1 2021, i.e. a margin of 1.6%), we had forecast, respectively, € 48.4m (+9% y-o-y) and € 0.5m (margin 0.1%). The prescription glasses activity was stable y-o-y over the quarter at € 20.8m (growth was barely positive in Q4 2021) whilst contact lenses posted growth of 13% (€ 15.8m) and 8% in s...